An antibody recognition unit can be engineered from linked heavy- and light-chain variable regions or from a single suitable variable domain. These formats have different structures to evaluate.
The original single-chain Fv work linked antibody heavy- and light-chain variable regions and tested binding after expression and refolding. Camelid heavy-chain antibody studies established a different architecture without light chains, underlying VHH-derived formats. More recent engineered-cell comparisons test the behavior of particular fragments in particular constructs. Format names describe architecture; they do not by themselves establish stability, specificity or therapeutic superiority. The first single-chain Fv joined the heavy- and light-chain variable domains of an anti-digoxin antibody with a 15-amino-acid linker (relative molecular mass 26,354); after refolding it showed digoxin specificity like the Fab and an association constant (3.2 x 10^7 per molar) about six-fold below the Fab's (Huston et al., 1988). Camel serum was found to contain IgG-like molecules of about 100 kDa made of heavy-chain dimers without light chains or CH1 (Hamers-Casterman et al., 1993). The NCBI imaging database entry gives about 150 kDa for an intact antibody and 25 to 30 kDa for a monovalent scFv; a 2021 review gives nanobody masses as low as about 15 kDa. Antigen-independent scFv clustering caused tonic signalling and exhaustion in specified CAR constructs (Long et al., 2015).
Shares Format-dependent binder function, Binders as targeting modules, Immune measurements and product evidence.
Shares Binders as targeting modules, Immune measurements and product evidence.
Shares Binders as targeting modules, Antibody.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/